OMER
OmerosDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bull case is that FDA approval has already de-risked the core asset, U.S. launch is underway, EMA review could add a second leg of upside, and the Novo Nordisk deal plus debt paydown bought enough runway for Omeros to commercialize without immediate distress [#8-K-2026-03-31] [#10-K-2026-03-31].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.3.
What can break
Commercial progress may be insufficient to prevent renewed equity issuance through the ATM or other financing.
Momentum
10
Value
41
Sentiment
64
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $11.00 · Bull $18.00 · Bear $6.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $33.00
Why
Momentum10 · Δ7d +6.6
Value41 · Δ7d -0.1
Sentiment64 · Δ7d +3.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
10
26% active weight
Current posture
7d trendImproving
Δ7d
+6.6
Δ21d
+8.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
64
34% active weight
Current posture
7d trendImproving
Δ7d
+3.3
Δ21d
-14.5
Why this grade
Composite grade D. Momentum 9.5 / Value 41.1 / Sentiment 64.3
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$696.97M
Beta
2.46
Shares Out
72.38M
P/E (TTM) · Derived
-182.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.99
Rev YoY
-100.0%
EPS YoY
-235.3%
Gross Margin
+84.8%
Op Margin
-
Net Debt
$235.21M
Current Ratio
3.03
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology